- Email: [email protected]
The effects of verapamil on coronary hemodynamics and vasomobility in patients with coronary artery disease
ABSTRACTS
Abstracts of Papers to be Presentedat
the 29th Annual
Scientific Session of the American College of Cardiology Houston, Texas, March 9 to 13, 1980 This year a record number of abstracts, 1755, were submitted for evaluation. Each was graded by 10 recognized authorities in the special field of interest. Acceptance of abstracts for presentation was based on grade ranking in proportion to total number of abstracts assigned by the authors in each category. Our membership has varied backgrounds and interests so that the Scientific Sessions were planned to maintain a balance between structured and abstract sessions. The total of 424 abstracts selected for presentation this year is a record for the College. The percent of submitted abstracts selected remains essentially unchanged from last year, i.e., 25 percent. The Program Committee is aware of the important role of the abstract sessions and regrets that many excellent studies could not be accepted. The Committee has sought and will continue to look for ways to expand the abstract sessions for future meetings. Arnold M. Weissler, MD, Chairman,
Program
29th Annual
Scientific Session
Richard P. Lewis,MD Co-Chairman, 29th Annual
MONDAY, MARCH 10, 1980 AM CORONARY ARTERY DISEASE: 10:30- 12:oo
ROLE OF VASOSPASM
Verapamil (V), a potent Ca2+-antagonist, is eTrective in exertional and rest angina with its mode of action remaining unclear. Its I.V. effects (0.145 mg/kg in 2 min with 0.005 mg/kg/min infusion) on mean aortic pressure (MAP), mean pulmonary wedge pressure (PCW), cardiac index (CI), coronary sinus flow (CSF), systemic resistance (SR), pulmonary resistance (PR), coronary resistance (CR) and myocardial oxygen consumption (MVO2) were determined in 7 pts during coronary angiography. Lumen cross sectional area at "normal" (An) and most narrowed (Amin) points and the stenosis flow resistance (RS) were determined by a computer-based angiographic analysis of 18 diseased coronary segments. Results (means&D; fincreased; +decreased; *p< .Ol): MAP-9 to 85+11 mmHg*); SRs (1280+320 to 1032? 272 dyne.sec.cm-s*); PCW+ (12?1 to 16?2 mmHg*) with insignificant changes in HR, PR and CI. MV02 decreased 18%+2% (N=3). Pressure-rate product (PRP) t 23?7%.
Control V
An (rnn2) 6.8i5 15%4"
Amin
(
Program
FACC Committee
Scientific Session
ANTI-ANGINAL ACTION OF VEHAPAMIL - A CONTROLLED STUDY
THE EFFECTS OF VERAPAMIL ON CORONARY HEMODYNAMICS AND VASOKIBILITY IN PATIENTS WITH CORONARY ARTERY DISEASE Christopher Y.C. Chew, MD; B. Greg Brown, MD; Maylene Wong, MD; Pravin M. Shah, MD; Bramah N. Singh, MD, Ph.D., VA Wadsworth Hospital, Los Angeles, California, and Edward L. Bolson,MD; Harold T. Dodge, MD, University of Washington, Seattle, Washington
CSF (ml/min) 102537 119*39
FACC
Committee
2,
2&.9 12%4*
Rs CR (dyne.sec.cm-sxl0a) 7?21 77?22 18%+* 52?17*
V. Balasubramanian, MD, FACC; A. Lahiri, MBBS; P. Sivam, MD; E.B. Raftery, MD, BSC, FACC, FRCP Northwick Park Hospital & Clinical Research Centre, Harrow, England. The anti-angina1 efficacy of verapamil hydrochloride, a calcium channel blocker, in a dose of 120 mgs t.i.d. was investigated utilisiug
Thus, verapamil decreased MAP, PRP, and MV02 while CSF tended to rise due to dilatation of both resistance and conductance coronary vessels. The results are consistent with the drug's observed salutary effects on myocardial ischemia in man.
February1980
The American
Journal of CARDIOLOGY
Volume
45
389
Abstracts of Papers to be Presentedat
the 29th Annual
Scientific Session of the American College of Cardiology Houston, Texas, March 9 to 13, 1980 This year a record number of abstracts, 1755, were submitted for evaluation. Each was graded by 10 recognized authorities in the special field of interest. Acceptance of abstracts for presentation was based on grade ranking in proportion to total number of abstracts assigned by the authors in each category. Our membership has varied backgrounds and interests so that the Scientific Sessions were planned to maintain a balance between structured and abstract sessions. The total of 424 abstracts selected for presentation this year is a record for the College. The percent of submitted abstracts selected remains essentially unchanged from last year, i.e., 25 percent. The Program Committee is aware of the important role of the abstract sessions and regrets that many excellent studies could not be accepted. The Committee has sought and will continue to look for ways to expand the abstract sessions for future meetings. Arnold M. Weissler, MD, Chairman,
Program
29th Annual
Scientific Session
Richard P. Lewis,MD Co-Chairman, 29th Annual
MONDAY, MARCH 10, 1980 AM CORONARY ARTERY DISEASE: 10:30- 12:oo
ROLE OF VASOSPASM
Verapamil (V), a potent Ca2+-antagonist, is eTrective in exertional and rest angina with its mode of action remaining unclear. Its I.V. effects (0.145 mg/kg in 2 min with 0.005 mg/kg/min infusion) on mean aortic pressure (MAP), mean pulmonary wedge pressure (PCW), cardiac index (CI), coronary sinus flow (CSF), systemic resistance (SR), pulmonary resistance (PR), coronary resistance (CR) and myocardial oxygen consumption (MVO2) were determined in 7 pts during coronary angiography. Lumen cross sectional area at "normal" (An) and most narrowed (Amin) points and the stenosis flow resistance (RS) were determined by a computer-based angiographic analysis of 18 diseased coronary segments. Results (means&D; fincreased; +decreased; *p< .Ol): MAP-9 to 85+11 mmHg*); SRs (1280+320 to 1032? 272 dyne.sec.cm-s*); PCW+ (12?1 to 16?2 mmHg*) with insignificant changes in HR, PR and CI. MV02 decreased 18%+2% (N=3). Pressure-rate product (PRP) t 23?7%.
Control V
An (rnn2) 6.8i5 15%4"
Amin
(
Program
FACC Committee
Scientific Session
ANTI-ANGINAL ACTION OF VEHAPAMIL - A CONTROLLED STUDY
THE EFFECTS OF VERAPAMIL ON CORONARY HEMODYNAMICS AND VASOKIBILITY IN PATIENTS WITH CORONARY ARTERY DISEASE Christopher Y.C. Chew, MD; B. Greg Brown, MD; Maylene Wong, MD; Pravin M. Shah, MD; Bramah N. Singh, MD, Ph.D., VA Wadsworth Hospital, Los Angeles, California, and Edward L. Bolson,MD; Harold T. Dodge, MD, University of Washington, Seattle, Washington
CSF (ml/min) 102537 119*39
FACC
Committee
2,
2&.9 12%4*
Rs CR (dyne.sec.cm-sxl0a) 7?21 77?22 18%+* 52?17*
V. Balasubramanian, MD, FACC; A. Lahiri, MBBS; P. Sivam, MD; E.B. Raftery, MD, BSC, FACC, FRCP Northwick Park Hospital & Clinical Research Centre, Harrow, England. The anti-angina1 efficacy of verapamil hydrochloride, a calcium channel blocker, in a dose of 120 mgs t.i.d. was investigated utilisiug
Thus, verapamil decreased MAP, PRP, and MV02 while CSF tended to rise due to dilatation of both resistance and conductance coronary vessels. The results are consistent with the drug's observed salutary effects on myocardial ischemia in man.
February1980
The American
Journal of CARDIOLOGY
Volume
45
389